Locations:
Search IconSearch

Research

22-CNR-3105958-CQD-SauterHero-650×450
September 6, 2022/Cancer/Research

Optimizing CAR T-Cell and Stem Cell Transplant Treatments

New BMT leadership looks to clinical research and cell therapy production to overcome treatment access limitations

22-CNR-3126458-CQD-Hero-650×450 PET radiotracer
August 31, 2022/Cancer/Research

Investigational PET Imaging Agent Being Explored as a Predictive Biomarker For Response to Standard Chemotherapies

Pilot Study at Cleveland Clinic is Testing Feasibility and Biodistribution

22-CNR-3191400-CQD-Hero-650×450
August 22, 2022/Cancer/Research

Distinct PHTS-related Breast Cancer Genomic Characteristics Discovered

Findings support need for personalized disease management

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

22-CNR-3103108-CQD-Hero-650×450-LRI flip
August 9, 2022/Cancer/Research

Tumors with Specific Genetic Mutations Show Response to Immune Checkpoint Blockade Therapy

Pathogenic POLE/POLD1 mutations lead to improved response to immune checkpoint blockade therapy

21-CNR-2544358-CQD-Hero-650×450 DCIS biosignature
August 4, 2022/Cancer/Research

Biosignatures Optimize Adjuvant Radiation Therapy Decisions in Patients with DCIS

Tumor genomics offer clues for identifying high risk of relapse

22-CNR-3001718-CQD-Hero-650x450S-WOG 1318 Phase 2 Trial
July 28, 2022/Cancer/Research

Phase 2 Study Shows Promise for Treating Older Adults with Ph-Negative B-ALL

Blinatumomab followed by POMP maintenance shows effectiveness for newly diagnosed patients

22-CNR-3036012-CQD-Hero-650×450 colorectal cancer
July 26, 2022/Cancer/Research

Patients with MSI-High Colorectal Cancer Sought for Immunotherapy Trial

Study to test efficacy of immunotherapy with chemotherapy and radiation

22-CNR-3055674-CQD-Hero-650×450 gliomas
July 22, 2022/Cancer/Research

New Paradigm Evolving for Treatment of Advanced Gliomas

Molecular targets may offer noncytotoxic treatment path

22-CNR-2813047-CQD-Hero-650×450 Gupta
July 14, 2022/Cancer/Research

MAIN-CAV Trial Investigates Maintenance Cabozantinib plus Avelumab in Metastatic Urothelial Cancer

Will avelumab plus cabozatinib outperform avelumab monotherapy as maintenance treatment?

BackPage 10 of 42Next

Advertisement

Ad